

## Keverprazan Hydrochloride: Adis Evaluation

### Key Points

- A potassium ion competitive acid blocker is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease
- Received its first approval on 15 February 2023 in China
- Approved for use in reflux oesophagitis and duodenal ulcer

### Summary

Keverprazan hydrochloride (凯普拉生) is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease.

Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer.

This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.